Literature DB >> 28122786

Intrinsic Clearance Assay Incubational Binding: A Method Comparison.

Sofia Chen1, Luna Prieto Garcia1, Fredrik Bergström1, Pär Nordell1, Ken Grime2.   

Abstract

The fraction of unbound drug (fuinc) in in vitro intrinsic clearance (CLint) incubation is an important parameter in the pursuit of accurate clearance predictions and is often predicted using algorithms based on drug lipophilicity measures. However, analysis of an AstraZeneca database suggests that simple lipophilicity alone is a relatively poor predictor of fuinc measured using equilibrium dialysis. He fuinc value can also be measured directly in CLint assays using multiple concentrations of hepatocytes or microsomal protein. Since this approach informs of the unbound drug concentration in the assay used to predict in vivo clearance, it should be considered the gold standard method. As a starting point for building better predictive algorithms we aimed to determine if equilibrium dialysis really is an appropriate assay for assessing fuinc Employing a large number of compounds with a wide range of lipophilicities, experiments were performed to measure fuinc using rat hepatocytes (RH) and human liver microsomes (HLM) in both assay formats. A high percentage (94% and 93% for HLM and RH, respectively) of the fuinc values were within 2-fold when the compound distribution coefficient describing the ratio of compound concentration in octanol and pH 7.4 buffer when the test system is at equilibrium (lipophilicity measure) (logD7.4) values were less than 3.5. However, with logD7.4 values greater than these, the agreement was considerably worse. Additional experimental data generated indicated that this discrepancy was likely due to failings in the direct method when drug binding is high. Thus, we conclude that unbound CLint can be indeed calculated indirectly by incorporating equilibrium dialysis data with measured CLint but that simple lipophilicity descriptors alone may be inadequate for predicting fuinc.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28122786     DOI: 10.1124/dmd.116.074138

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Authors:  Nigel J Waters; R Scott Obach; Li Di
Journal:  Methods Mol Biol       Date:  2021

2.  Metabolism and pharmacokinetics characterization of metarrestin in multiple species.

Authors:  Elias C Padilha; Pranav Shah; Amy Q Wang; Marc D Singleton; Emma A Hughes; Dandan Li; Kelly A Rice; Kylie M Konrath; Samarjit Patnaik; Juan Marugan; Udo Rudloff; Xin Xu
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-17       Impact factor: 3.333

Review 3.  Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization.

Authors:  Jasleen K Sodhi; Leslie Z Benet
Journal:  J Med Chem       Date:  2021-03-25       Impact factor: 7.446

4.  A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling.

Authors:  Johan Wernevik; Fredrik Bergström; Anna Novén; Johan Hulthe; Linda Fredlund; Dan Addison; Jan Holmgren; Per-Erik Strömstedt; Erika Rehnström; Thomas Lundböck
Journal:  Assay Drug Dev Technol       Date:  2020-05-14       Impact factor: 1.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.